Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities

American Journal of Pathology

Volumn 175, Issue 5, 2009, Pages 2053-2062

  Wilson, Susan ^a   Hashamiyan, Saadat ^a   Clarke, Lorne ^a   Saftig, Paul ^b   Mort, John ^c   Dejica, Valeria M ^c   Brömme, Dieter ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF KIEL   (Germany)

^c SHRINERS HOSPITAL FOR CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN K; COLLAGEN TYPE 2; DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVITY; COLLAGEN DEGRADATION; CONTROLLED STUDY; GROWTH PLATE; HURLER SYNDROME; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; WILD TYPE;

EID: 73649099843     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.090211     Document Type: Article

References (47)

1. Neufeld EF, Muenzer J: The Mucopolysaccharidoses. New York, McGraw-Hill, 2001, pp 3419-3428
2. Burrow TA, Hopkin RJ, Leslie ND, Tinkle BT, Grabowski GA: Enzyme reconstitution/replacement therapy for lysosomal storage diseases. Curr Opin Pediatr 2007, 19:628-635
3. Yasuda Y, Kaleta J, Bromme D: The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev 2005, 57:973-993
4. Gelb BD, Shi GP, Chapman HA, Desnick RJ: Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996, 273:1236-1238
5. Everts V, Hou WS, Rialland X, Tigchelaar W, Saftig P, Bromme D, Gelb BD, Beertsen W: Cathepsin K deficiency in pycnodysostosis results in accumulation of non-digested phagocytosed collagen in fibroblasts. Calcif Tissue Int 2003, 73:380-386
6. Gelb BD, Brömme D, Desnick RJ: Pycnodysostosis: Cathepsin K deficiency. The Metabolic and Molecular Bases of Inherited Diseases. Edited by CR Sriver, AL Beaudet, D Valle, W Sly. New York, McGraw-Hill, Inc., 2001, pp 3453-3468
7. Fratzl-Zelman N, Valenta A, Roschger P, Nader A, Gelb BD, Fratzl P, Klaushofer K: Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis. J Clin Endocrinol Metab 2004, 89:1538-1547
8. Li Z, Hou WS, Bromme D: Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates. Biochemistry 2000, 39:529-536
9. Li Z, Hou WS, Escalante-Torres CR, Gelb BD, Bromme D: Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate. J Biol Chem 2002, 277:28669-28676
10. Li Z, Kienetz M, Cherney MM, James MN, Bromme D: The crystal and molecular structures of a cathepsin K:chondroitin sulfate complex. J Mol Biol 2008, 383:78-91
11. Li Z, Yasuda Y, Li W, Bogyo M, Katz N, Gordon RE, Fields GB, Bromme D: Regulation of collagenase activities of human cathepsins by glycosaminoglycans. J Biol Chem 2004, 279:5470-5479
12. Ballock RT, O'Keefe RJ: The biology of the growth plate. J Bone Joint Surg Am 2003, 85-A:715-726
13. Saftig P, Wehmeyer O, Hunziker E, Jones S, Boyde A, Rommerskirch W, von Figura K: Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin K-deficient mice. Proc Natl Acad Sci USA 1998, 95:13453-13458
14. Clarke LA, Russell CS, Pownall S, Warrington CL, Borowski A, Dimmick JE, Toone J, Jirik FR: Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene. Hum Mol Genet 1997, 6:503-511
15. Xia L, Kilb J, Wex H, Lipyansky A, Breuil V, Stein L, Palmer JT, Dempster DW, Brömme D: Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption cathepsin K-activity by peptidyl vinyl sulfones. Biol Chem 1999, 380:679-687
16. Dejica VM, Mort JS, Laverty S, Percival MD, Antoniou J, Zukor DJ, Poole AR: Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage. Am J Pathol 2008, 173:161-169
17. Hoebertz A, Arnett TR: Isolated osteoclast cultures. Bone Research Protocols. Edited by MH Helfrich, SH Ralston. Totowa NJ, Humana Press, 2003, pp 53-64
18. Linnevers CJ, McGrath ME, Armstrong R, Mistry FR, Barnes M, Klaus JL, Palmer JT, Katz BA, Brömme D: Expression of human cathepsin K in Pichia pastoris and preliminary crystallographic studies of an inhibitor complex. Protein Science 1997, 6:919-921
19. Palmer JT, Rasnick D, Klaus JL, Brömme D: Vinyl sulfones as mechanism-based cysteine protease inhibitors. J Med Chem 1995, 38:3193-3196
20. Riese RJ, Wolf P, Bromme D, Natkin LR, Villadangos JA, Ploegh HL, Chapman HA: Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 1996, 4:357-366
21. Graebert KS, Bauch H, Neumuller W, Brix K, Herzog V: Epithelial folding in vitro: studies on the cellular mechanism underlying evagination of thyrocyte monolayers. Exp Cell Res 1997, 231:214-225
22. Wilson SR, Peters C, Saftig P, Bromme D: Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. J Biol Chem 2009, 284:2584-2592
23. Lakkakorpi PT, Vaananen HK: Kinetics of the osteoclast cytoskeleton during the resorption cycle in vitro. J Bone Miner Res 1991, 8:817-826
24. Haskins ME, Otis EJ, Hayden JE, Jezyk PF, Stramm L: Hepatic storage of glycosaminoglycans in feline and canine models of mucopolysaccharidoses I, VI, and VII. Vet Pathol 1992, 29:112-119
25. Chung S, Ma X, Liu Y, Lee D, Tittiger M, Ponder KP: Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice. Mol Genet Metab 2007, 90:181-192
26. Russell C, Hendson G, Jevon G, Matlock T, Yu J, Aklujkar M, Ng KY, Clarke LA: Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clin Genet 1998, 53:349-361
27. Birkenmeier EH, Davisson MT, Beamer WG, Ganschow RE, Vogler CA, Gwynn B, Lyford KA, Maltais LM, Wawrzyniak CJ: Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency. J Clin Invest 1989, 83:1258-1266
28. Haskins ME, Aguirre GD, Jezyk PF, Desnick RJ, Patterson DF: The pathology of the feline model of mucopolysaccharidosis I. Am J Pathol 1983, 112:27-36
29. Abreu S, Hayden J, Berthold P, Shapiro IM, Decker S, Patterson D, Haskins M: Growth plate pathology in feline mucopolysaccharidosis VI. Calcif Tissue Int 1995, 57:185-190
30. Evers M, Saftig P, Schmidt P, Hafner A, McLoghlin DB, Schmahl W, Hess B, von Figura K, Peters C: Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI. Proc Natl Acad Sci USA 1996, 93:8214-8219
31. Li X, Wang R, Li Y, Tang L, Hu J, Xu A: Epiphyseal and physeal cartilage: normal gadolinium-enhanced MR imaging. J Huazhong Univ Sci Technolog Med Sci 2005, 25:209-211
32. Herati RS, Knox VW, O'Donnell P, D'Angelo M, Haskins ME, Ponder KP: Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy. Mol Genet Metab 2008, 95:142-151
33. Metcalf JA, Zhang Y, Hilton MJ, Long F, Ponder KP: Mechanism of shortened bones in mucopolysaccharidosis VII. Mol Genet Metab 2009
34. Bromme D, Okamoto K: Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing, and tissue distribution. Biol Chem Hoppe Seyler 1995, 376:379-384
35. Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee-Rykaczewski E, Coleman L, Rieman D, Barthlow R, Hastings G, Gowen M: Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 1996, 271:12511-12516
36. Sanderson RD, Yang Y, Suva LJ, Kelly T: Heparan sulfate proteoglycans and heparanase-partners in osteolytic tumor growth and metastasis. Matrix Biol 2004, 23:341-352
37. Nakano K, Okada Y, Saito K, Tanaka Y: Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. Arthritis Rheum 2004, 50:2450-2458
38. Dai J, Rabie AB: VEGF: an essential mediator of both angiogenesis and endochondral ossification. J Dent Res 2007, 86:937-950
39. Simonaro CM, D'Angelo M, He X, Eliyahu E, Shtraizent N, Haskins ME, Schuchman EH: Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol 2008, 172:112-122
40. Hou W-S, Li W, Keyszer G, Weber E, Levy R, Klein MJ, Gravallese EM, Goldring SR, Bromme D: Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum 2002, 46:663-674
41. Weinstein RS, Roberson PK, Manolagas SC: Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009, 360:53-62
42. Nakamura H, Ozawa H: Immunohistochemical localization of heparan sulfate proteoglycan in rat tibiae. J Bone Miner Res 1994, 9:1289-1299
43. Byers RJ, Denton J, Hoyland JA, Freemont AJ: Differential patterns of altered bone formation in different bone compartments in established osteoporosis. J Clin Pathol 1999, 52:23-28
44. Byers S, Nuttall JD, Crawley AC, Hopwood JJ, Smith K, Fazzalari NL: Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI. Bone 1997, 21:425-431
45. Nuttall JD, Brumfield LK, Fazzalari NL, Hopwood JJ, Byers S: Histomorphometric analysis of the tibial growth plate in a feline model of mucopolysaccharidosis type VI. Calcif Tissue Int 1999, 65:47-52
46. Simonaro CM, D'Angelo M, Haskins ME, Schuchman EH: Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 2005, 57:701-707
47. Monroy MA, Ross FP, Teitelbaum SL, Sands MS: Abnormal osteoclast morphology and bone remodeling in a murine model of a lysosomal storage disease. Bone 2002, 30:352-359